Evolution of the NCCN Guidelines for Kidney Cancer -Tian Zhang

(Length of Discussion: 12 min)

Tian Zhang and Charles Ryan highlight recent updates in the NCCN treatment guidelines for kidney cancer resulting from data leading to changes in treatment options. Incorporation of initial diagnosis, disease biology, risk category, and clinical factors assist with selecting the most appropriate therapy for these patients.

Biographies:

Tian Zhang, MD, Assistant Professor of Medicine in the Division of Medical Oncology and the Department of Medicine and a member of the Duke Cancer Institute

Charles J. Ryan, MD